Clinical trials located in

Mikołów

Mikołów city is located in Poland. Currently, 5 clinical trials are being conducted in this city.

Mikołów, a city in southern Poland, boasts a rich history dating back to the 13th century. Nestled in the Silesian Voivodeship, it was once a hub for coal mining and energy industries. The city’s architectural landscape is a testament to its historical depth, featuring the Gothic St. Adalbert church and the unique Market Square that reflects its medieval origins. Mikołów is also known for its green spaces, including the scenic Podlesie Arboretum, showcasing the region’s natural beauty. Despite its industrial past, Mikołów has transformed into a vibrant community with a focus on culture and education.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Discovering a new drug for atopic dermatitis

    This clinical trial aims to evaluate the safety and effectiveness of LEO 138559, a new medication for adults with moderate-to-severe atopic dermatitis, a challenging skin condition. The study tests four different doses of LEO 138559 against a placebo (a treatment without the active drug) over 36 weeks. Participants, who will be randomly assigned to one of the doses or placebo, will receive injections just under the skin at regular clinic visits. The trial includes a 4-week screening phase, a 16-week treatment phase, and a 16-week follow-up. Participants will visit the clinic 17 times and keep a daily electronic diary to track their skin condition and quality of life. This study is crucial for understanding how well LEO 138559 works and its safety in treating this persistent skin condition.

    • LEO 138559- new potential medication for atopic dermatitis
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.